# Magdalena Jonikas

> Magdalena Jonikas is a Series A investor at Syncona Partners LLP backing Life Science and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Syncona Partners LLP](https://shizune.co/investors/profile/syncona-partners-llp)
- Location: London, United Kingdom
- Total investments: 4
- Last investment: Apr 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/magdalena-jonikas-63580a3/
- Website: https://x.com/magdalena_a_j
- Facebook: https://www.facebook.com/magdalena.jonikas

Magdalena Jonikas is a Series A investor at Syncona Partners LLP in London focused on Life Science and Medical. Magdalena Jonikas is based out of London, England, and is the Partner of Syncona Partners LLP and Non-Executive Board Director at Mosaic Therapeutics. Magdalena previously served as the Non Executive Director at Azeria Therapeutics. Magdalena Jonikas attended Stanford University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 50% |
| Medical | 1 | 25% |
| Therapeutics | 1 | 25% |
| Biotechnology | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mosaic Therapeutics | Mosaic Therapeutics is an oncology therapeutics company that develops targeted combination therapies for cancer patients. The company utilizes a proprietary platform to identify synergistic drug combinations based on biomarker-defined patient populations, aiming to improve the efficacy and durability of responses. Mosaic Therapeutics' researchfocuses on identifying specific biomarkers that can be targeted with tailored drug combinations, enhancing the effectiveness of treatments for individual patients. | $28M | Series A | Apr 04, 2023 |  |
| OMass Therapeutics | OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $94.7M | Series B | Apr 27, 2022 |  |
| OMass Therapeutics | OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $35.8M | Series A | Feb 17, 2020 |  |
| OMass Therapeutics | OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $22.8M | Series A | Nov 21, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 2 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 1 deal together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 1 deal together
- [Syncona Partners LLP](https://shizune.co/investors/profile/syncona-partners-llp) — VC Fund, 1 deal together

## About Syncona Partners LLP

VC Fund · London, United Kingdom

Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.They seek to partner with the best, brightest and most ambitious minds in scienceto build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.

5 contacts available at Syncona Partners LLP.

| Name | Title | Profile |
| --- | --- | --- |
| Edward Hodgkin | Partner | https://shizune.co/investors/profile/edward-hodgkin |
| Magdalena Jonikas | Partner | https://shizune.co/investors/profile/magdalena-jonikas-90a8 |
| Chris Hollowood | Chief Investment Officer | https://shizune.co/investors/profile/chris-hollowood |
| Chris Hollowood | Chief Investment Officer | https://shizune.co/investors/profile/christopher-hollowood |
| Christian Groendahl | Partner | https://shizune.co/investors/profile/christian-groendahl |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Magdalena Jonikas invest in?

Magdalena Jonikas invests primarily in Life Science, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Magdalena Jonikas last invest?

The most recent investment recorded for Magdalena Jonikas closed in Apr 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co